Blue Owl takes 7.37% stake in ImageneBio

ImageneBio, Inc. received a Schedule 13G filing showing that Blue Owl Capital Holdings LP beneficially owns 823,785 shares of ImageneBio common stock.

Rhea-AI Filing Summary

ImageneBio, Inc. received a Schedule 13G filing showing that Blue Owl Capital Holdings LP beneficially owns 823,785 shares of ImageneBio common stock. This represents 7.37% of the company’s outstanding common shares, based on 11,181,672 shares reported as outstanding as of November 3, 2025.

Blue Owl reports sole voting and dispositive power over all 823,785 shares and no shared power. The firm certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of ImageneBio.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake in ImageneBio (IMA) does Blue Owl Capital report on this Schedule 13G?

Blue Owl Capital Holdings LP reports beneficial ownership of 823,785 shares of ImageneBio common stock. This equals 7.37% of the outstanding common shares, based on 11,181,672 shares outstanding as of November 3, 2025, as cited in the filing.

Does Blue Owl Capital have voting and dispositive power over its ImageneBio (IMA) shares?

Blue Owl Capital reports sole voting power over 823,785 ImageneBio shares and sole dispositive power over the same amount. The filing shows zero shared voting power and zero shared dispositive power, indicating control over how these particular shares are voted and disposed.

Is Blue Owl Capital’s ImageneBio (IMA) investment intended to influence control of the company?

The filing states the securities were acquired and are held in the ordinary course of business. It further certifies they were not acquired and are not held to change or influence control of ImageneBio, consistent with a passive investment reported on Schedule 13G.

What ownership threshold does Blue Owl Capital’s ImageneBio (IMA) position exceed?

Blue Owl Capital’s 7.37% stake in ImageneBio exceeds the 5% beneficial ownership threshold that triggers a Schedule 13G filing. The document confirms the position is above 5%, and that items regarding ownership of 5% or less are marked not applicable.

How was Blue Owl Capital’s 7.37% ownership in ImageneBio (IMA) calculated?

The percentage is based on 11,181,672 ImageneBio common shares outstanding as of November 3, 2025. That share count is referenced from ImageneBio’s Form S-1 registration statement, and Blue Owl’s 823,785 shares are expressed as 7.37% of that total.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/12/2026 - 04:10 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

ImageneBio, Inc.

(Name of Issuer)

Common Stock, $0.001 par value per share

(Title of Class of Securities)

45175G207

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 45175G207

1

Names of Reporting Persons

Blue Owl Capital Holdings LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 823,785.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 823,785.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

823,785.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.37 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The reported percentage is calculated based on 11,181,672 shares of Common Stock outstanding as of November 3, 2025, as reported in the Issuer's registration statement on Form S-1 filed with the Securities and Exchange Commission on November 12, 2025.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: ImageneBio, Inc.
(b)	Address of issuer's principal executive offices: 12526 High Bluff Drive, Suite 345, San Diego, California, 92130
Item 2.
(a)	Name of person filing: This statement is filed by the Blue Owl Capital Holdings LP, referred to herein as the "Reporting Person."
(b)	Address or principal business office or, if none, residence: 399 Park Avenue New York, New York 10022
(c)	Citizenship: See response to Item 4 on the cover page.
(d)	Title of class of securities: Common Stock, $0.001 par value per share
(e)	CUSIP No.: 45175G207
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See response to Item 9 on the cover page. The filing of this statement shall not be deemed an admission by any of the Reporting Persons, of beneficial ownership of the reported securities for purposes of Section 13(d) or Section 13(g) or for any other purpose.
(b)	Percent of class: See response to Item 11 on the cover page.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See response to Item 5 on the cover page.
	(ii) Shared power to vote or to direct the vote: See response to Item 6 on the cover page.
	(iii) Sole power to dispose or to direct the disposition of: See response to Item 7 on the cover page.
	(iv) Shared power to dispose or to direct the disposition of: See response to Item 8 on the cover page.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Blue Owl Capital Holdings LP

Signature:	/s/ Karen Hager
Name/Title:	Karen Hager/Chief Compliance Officer
Date:	02/12/2026